We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effect of proton pump inhibitors and vonoprazan on the development of 'gastric mucosal redness'.
- Authors
Shinozaki, Satoshi; Osawa, Hiroyuki; Miura, Yoshimasa; Hayashi, Yoshikazu; Sakamoto, Hirotsugu; Yano, Tomonori; Kawarai Lefor, Alan; Yamamoto, Hironori
- Abstract
The safety of long-term proton pump inhibitor (PPI) and vonoprazan (VPZ) use is a relatively recent concern. Gastric mucosal redness was reported as a VPZ-associated lesion in a previous study. The aim of this study was to investigate the prevalence and risk factors for gastric mucosal redness. Between December 2020 and November 2021, 1,101 patients who underwent esophagogastroduodenoscopy were reviewed. The cohort was divided into four groups: Control (n=580), histamine-2 receptor antagonist (H2RA) (n=65), PPI (n=146) and VPZ groups (n=310). Gastric mucosal redness was present in 48/1,101 patients (4%). The prevalence in controls, H2RA, PPI and VPZ groups was 1.9% (11/580), 1.5% (1/65), 6.2% (9/146) and 8.7% (27/310), respectively. Both the PPI and VPZ groups had a significantly higher prevalence of gastric mucosal redness compared with the control group (P<0.001). In the multivariate analysis, PPI and VPZ use were significantly associated with gastric mucosal redness. Fundic gland polyps, gastric hyperplastic polyps, multiple white and flat elevated lesions, cobblestone-like mucosa, and stardust gastric mucosa were also significantly associated with PPI and VPZ use in the multivariate analysis. Back-to-back analysis showed that gastric mucosal redness was not seen before starting PPI/VPZ in most patients. The duration of treatment with VPZ was investigated to determine if it affected the prevalence of gastric mucosal redness. There were no significant differences in treatment duration among patients with and without gastric mucosal redness (mean ± standard deviation: 3.0±1.5 vs. 2.5±1.4 years, P=0.077). In conclusion, the prevalence of gastric mucosal redness was low but was associated with PPI and VPZ use.
- Subjects
PROTON pump inhibitors; GASTRIC mucosa; H2 receptor antagonists; MULTIVARIATE analysis; STANDARD deviations; HELICOBACTER pylori infections
- Publication
Biomedical Reports, 2022, Vol 16, Issue 6, pN.PAG
- ISSN
2049-9434
- Publication type
Article
- DOI
10.3892/br.2022.1534